Photodynamic therapy (PDT) with sulfonated aluminum phthalocyanine (AlSPC), i.e., AlSPC-PDT, in two murine tumor models is reported here. The encouraging therapy results were observed in S₁₈₀ fibrosarcoma transplanted in white mice of the Kunming line and in human hepatocellular carcinoma transplanted in balb/c nu/nu nude mice. The experimental tumors in the mice were chosen of those 0.5 - 0.8 cm in diameter and 0.4 - 0.7 cm in thickness. Photofrin II (PII) and Photosensitizing drug-007 (PSD-007), two kinds of porphyrin derivative dyes, were chosen as the contrast photosensitizers of AlSPC. A dose of 10 mg/kg AlSPC or PII or PSD-007 was given (iv). The dose of light (600 - 750 nm) was 180 J/cm². `Cure (short-term)' was defined as regression of neoplastic tissue to a non-palpable tumor within 14 days after PDT. `Cure (long-term)' was defined as absence of local tumor tissue and tumor metastasis on gross and microscopic examinations within 107 days after PDT. The curative results suggest that AlSPC may be a more effective sensitizer than both PII and PSD-007.

Date Published: 5 March 1993
PDF: 7 pages
Proc. SPIE 1616, International Conference on Photodynamic Therapy and Laser Medicine, (5 March 1993); doi: 10.1117/12.137032

Published in SPIE Proceedings Vol. 1616:
International Conference on Photodynamic Therapy and Laser Medicine
Junheng Li M.D., Editor(s)